The immunodiagnostic tests recommended by the International Myeloma Working Group (IMWG) for the initial symptomatic screening of patients for suspected monoclonal gammopathy such as multiple myeloma include serum protein electrophoresis (SPEP), serum immunofixation, and serum free light chains
(free kappa and free lambda with ratio).
Pulmonary light chain
deposition disease: report of five cases and review of the literature.
2005) On the optimal ratio of heavy to light chain
genes for efficient recombinant antibody production by CHO cells.
By omitting the reducing step after capturing immunoglobulins with antisera to [kappa] and [lambda] light chains
, they have essentially developed an MS version of the serum free light chain
immunoassay, made specific for monoclonal free light chain
by visual inspection of the mass spectra (9).
Serum-free light chain
assessment in hepatitis C virus-related lymphoproliferative disorders.
Cogne, "Role of light chain
variable region in myeloma with light chain
deposition disease: evidence from an experimental model," Blood, vol.
Serum free light chains
in the diagnosis and monitoring of patients with plasma cell dyscrasias.
TeNT is produced as a single polypeptide (approximately 150 kDa) and subsequently cleaved to a two-chain active holotoxin, in which a 50 kDa N-terminal Light Chain
(LC) and a 100 kDa C-terminal Heavy Chain (HC) are linked by a single disulphide bond 3'4.
While overt biclonal myeloma with obvious light chain
restriction is well described, (18) to our knowledge a case of "oligosecretory" biclonal myeloma detectable only by PCR is not, prompting this report.
Another important role of the myosin light chain
is regulatory function.
This peptide, made by Fmoc Chemistry (Ansynth, Roosendaal, the Netherlands), inhibits free light chain
activity but "does not interfere with IgE-or IgG-mediated mast cell activation.
Monoclonal immunoglobulin deposition diseases (MIDD) include primary and light chain
Protein studies (by nephelometry) showed a kappa light chain
Polyclonal B cell hyperactivity, hypersecretion of antibodies and also increased local synthesis may be responsible for the increase in free light chain
levels in relation to disease activity or relapses of disease.
Chapters address identification of amyloid fibrils, in vivo imaging of amyloid fibrils, diagnosis and classification, pathogenesis of systemic amyloidosis, supportive care, response assessment and prognosis in evaluating patients with immunoglobin light chain
amyloidosis, amyloid heart disease, amyloid neuropathy, treatment of immunoglobin light chain
amyloidosis, high dose therapy with stem cell replacement, transthyretin amyloidosis, and rare forms of amyloidosis.